Literature DB >> 19706677

Dopamine regulates phosphorylation of VEGF receptor 2 by engaging Src-homology-2-domain-containing protein tyrosine phosphatase 2.

Sutapa Sinha1, Pawan Kumar Vohra, Resham Bhattacharya, Shamit Dutta, Shirshendu Sinha, Debabrata Mukhopadhyay.   

Abstract

Vascular endothelial growth factor (VEGF)-induced receptor phosphorylation is the crucial step for initiating downstream signaling pathways that lead to angiogenesis or related pathophysiological outcomes. Our previous studies have shown that the neurotransmitter dopamine could inhibit VEGF-induced phosphorylation of VEGF receptor 2 (VEGFR-2), endothelial cell proliferation, migration, microvascular permeability, and thus, angiogenesis. In this study, we address the mechanism by which VEGFR-2 phosphorylation is regulated by dopamine. Here, we demonstrate that D2 dopamine receptor (D2DR) colocalizes with VEGFR-2 at the cell surface. Dopamine pretreatment increases the translocation and colocalization of Src-homology-2-domain-containing protein tyrosine phosphatase (SHP-2) with D2DR at the cell surface. Dopamine administration leads to increased VEGF-induced phosphorylation of SHP-2 and this increased phosphorylation parallels the increased phosphatase activity of SHP-2. Active SHP-2 then dephosphorylates VEGFR-2 at Y951, Y996 and Y1059, but not Y1175. We also observe that SHP-2 knockdown impairs the dopamine-regulated inhibition of VEGF-induced phosphorylation of VEGFR-2 and, subsequently, Src phosphorylation and migration. Our data establish a novel role for SHP-2 phosphatase in the dopamine-mediated regulation of VEGFR-2 phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19706677      PMCID: PMC2736867          DOI: 10.1242/jcs.053124

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  45 in total

Review 1.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

Authors:  Benjamin G Neel; Haihua Gu; Lily Pao
Journal:  Trends Biochem Sci       Date:  2003-06       Impact factor: 13.807

2.  The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor.

Authors:  S Basu; J A Nagy; S Pal; E Vasile; I A Eckelhoefer; V S Bliss; E J Manseau; P S Dasgupta; H F Dvorak; D Mukhopadhyay
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

3.  Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products.

Authors:  H F Dvorak; N S Orenstein; A C Carvalho; W H Churchill; A M Dvorak; S J Galli; J Feder; A M Bitzer; J Rypysc; P Giovinco
Journal:  J Immunol       Date:  1979-01       Impact factor: 5.422

Review 4.  Leaky tumor vessels: consequences for tumor stroma generation and for solid tumor therapy.

Authors:  H F Dvorak
Journal:  Prog Clin Biol Res       Date:  1990

Review 5.  Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis.

Authors:  Masabumi Shibuya
Journal:  BMB Rep       Date:  2008-04-30       Impact factor: 4.778

6.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

Authors:  R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

7.  TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism.

Authors:  Dong-Wan Seo; Hongmei Li; Liliana Guedez; Paul T Wingfield; Tere Diaz; Rita Salloum; Bei-yang Wei; William G Stetler-Stevenson
Journal:  Cell       Date:  2003-07-25       Impact factor: 41.582

Review 8.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

Review 9.  The nigrostriatal system in Parkinson's disease.

Authors:  A M Graybiel; E C Hirsch; Y Agid
Journal:  Adv Neurol       Date:  1990

Review 10.  Role of dopamine in malignant tumor growth.

Authors:  S Basu; P S Dasgupta
Journal:  Endocrine       Date:  2000-06       Impact factor: 3.925

View more
  21 in total

1.  Dopamine inhibits pulmonary edema through the VEGF-VEGFR2 axis in a murine model of acute lung injury.

Authors:  Pawan K Vohra; Luke H Hoeppner; Gunisha Sagar; Shamit K Dutta; Sanjay Misra; Rolf D Hubmayr; Debabrata Mukhopadhyay
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-10-14       Impact factor: 5.464

2.  Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma.

Authors:  Saiyin Hexige; Christine M Ardito-Abraham; Yanhua Wu; Youheng Wei; Yuan Fang; Xu Han; Jianang Li; Ping Zhou; Qing Yi; Anirban Maitra; Jun O Liu; David A Tuveson; Wenhui Lou; Long Yu
Journal:  J Pathol       Date:  2015-02-17       Impact factor: 7.996

3.  Role of Dopamine and D2 Dopamine Receptor in the Pathogenesis of Inflammatory Bowel Disease.

Authors:  Ganna Tolstanova; Xiaoming Deng; Amrita Ahluwalia; Brankica Paunovic; Alona Prysiazhniuk; Lyudmyla Ostapchenko; Andrzej Tarnawski; Zsuzsanna Sandor; Sandor Szabo
Journal:  Dig Dis Sci       Date:  2015-05-14       Impact factor: 3.199

Review 4.  Modulation of VEGF receptor 2 signaling by protein phosphatases.

Authors:  Federico Corti; Michael Simons
Journal:  Pharmacol Res       Date:  2016-11-23       Impact factor: 7.658

5.  Von Hippel-Lindau gene product directs cytokinesis: a new tumor suppressor function.

Authors:  Sutapa Sinha; Gourish Mondal; Eun Ju Hwang; Da Woon Han; Shamit K Dutta; Seethalakshmi Iyer; S Ananth Karumanchi; Keun Il Kim; Fergus J Couch; Debabrata Mukhopadhyay
Journal:  J Cell Sci       Date:  2011-06-07       Impact factor: 5.285

Review 6.  Vascular permeability to plasma, plasma proteins, and cells: an update.

Authors:  Harold F Dvorak
Journal:  Curr Opin Hematol       Date:  2010-05       Impact factor: 3.284

7.  Thrombospondin-1 modulates VEGF signaling via CD36 by recruiting SHP-1 to VEGFR2 complex in microvascular endothelial cells.

Authors:  Ling-Yun Chu; Devi Prasadh Ramakrishnan; Roy L Silverstein
Journal:  Blood       Date:  2013-07-29       Impact factor: 22.113

8.  Endothelial cell-specific chemotaxis receptor (ECSCR) enhances vascular endothelial growth factor (VEGF) receptor-2/kinase insert domain receptor (KDR) activation and promotes proteolysis of internalized KDR.

Authors:  Sreenivasulu Kilari; Indulekha Remadevi; Baofeng Zhao; Jing Pan; Robert Miao; Ramani Ramchandran; Paula E North; Ming You; Nader Rahimi; George A Wilkinson
Journal:  J Biol Chem       Date:  2013-02-07       Impact factor: 5.157

9.  β₂-glycoprotein I inhibits VEGF-induced endothelial cell growth and migration via suppressing phosphorylation of VEGFR2, ERK1/2, and Akt.

Authors:  Wen-Chin Chiu; Jan-Yu Lin; Tzong-Shyuan Lee; Li-Ru You; An-Na Chiang
Journal:  Mol Cell Biochem       Date:  2012-09-06       Impact factor: 3.396

10.  Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells.

Authors:  Luke H Hoeppner; Ying Wang; Anil Sharma; Naureen Javeed; Virginia P Van Keulen; Enfeng Wang; Ping Yang; Anja C Roden; Tobias Peikert; Julian R Molina; Debabrata Mukhopadhyay
Journal:  Mol Oncol       Date:  2014-08-30       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.